Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2001 Mar;6(2):81-94.
doi: 10.1023/a:1011428824771.

The role of interleukin-1 in the failing heart

Affiliations
Review

The role of interleukin-1 in the failing heart

C S Long. Heart Fail Rev. 2001 Mar.

Abstract

The prevalence of congestive heart failure and its continued poor prognosis despite presently available therapeutic options emphasize the importance of pursuing the observations suggesting an important role for an immunomodulatory approach to decompensated cardiac failure. Furthermore, there are several pieces of background information that suggest that cytokines like IL-1 may play a significant role in the pathogenesis of several forms of myocardial dysfunction. Although it seems clear that IL-1 is not acting alone under circumstances of myocardial injury, but in concert with other pro-inflammatory molecules and their effectors, we believe that continued investigations into the cytokine hypothesis will ultimately increase the understanding of how pro-inflammatory molecules influence myocardial function and how the modulation of such factors may improve the myocardial response to injury. The specific observations that emphasize the importance of pursuing a substantive role for IL-1 in this process are: (1) IL-1 is elevated in several cardiac disease states, (2) IL-1 is produced by myocardial cells themselves in response to injury, (3)The alterations in gene expression seen in response IL-1 resembles in many ways the phenotype of the failing heart, and (4) The co-localization of the IL-1 response with that of several previously described negative transcriptional regulators (making them potential targets for therapeutic manipulation).

PubMed Disclaimer

References

    1. J Biol Chem. 1997 Feb 21;272(8):4836-42 - PubMed
    1. Cardiovasc Res. 1993 Aug;27(8):1486-90 - PubMed
    1. J Am Coll Cardiol. 1999 Dec;34(7):2061-7 - PubMed
    1. Proc Natl Acad Sci U S A. 1993 Aug 1;90(15):7054-8 - PubMed
    1. J Interferon Cytokine Res. 1999 Jun;19(6):645-53 - PubMed

Publication types

LinkOut - more resources